AB Science reports Phase 1 AML results, patent updates
AB Science said six patients treated in Stage 3 of Phase 1 for AB8939 plus Venetoclax in AML showed no dose-limiting toxicity, and four achieved an objective response. The company also said Japan granted a patent for masitinib in progressive multiple sclerosis and that the USPTO issued a notice of allowance for a mCRPC